Powered By

Allergan Receives FDA Approval For OZURDEX(R) As Treatment Option For Non-Infectious Uveitis Affecting The Posterior ...


Published:Sat, 25 Sep 2010 05:17:08 -0700 
Allergan, Inc. (NYSE: AGN) announced that the United States Food and Drug Administration (FDA) has approved OZURDEX(R) (dexamethasone intravitreal implant) 0.7 mg for the treatment of non-infectious ocular inflammation, or uveitis, affecting the posterior segment of the eye. Uveitis is characterized by inflammation of the eyes uvea, which is the middle vascular layer consisting of the iris ......

Read More...


del.icio.us      |  Digg   |  Reddit   |   Add to Mixx!


More Articles
News Headlines